{"classes":[{"categories":[{"measurements":[{"comment":"There were too few events (disease progression or death) to estimate the third quartile.","groupId":"OG000","lowerLimit":"275.0","upperLimit":"NA","value":"449.0"},{"groupId":"OG001","lowerLimit":"337.0","upperLimit":"1016.0","value":"455.0"}]}]}],"denomUnitsSelected":"events","denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"15"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"9"}],"units":"events"}],"description":"Duration of response is defined as the time from the initial response to relapse/disease progression (DP) or death. DP for CR is defined as the reappearance of the IgM protein, new signs/symptoms attributable to WM, evidence of active disease or recurrence of bone marrow involvement by lymphoplasmacytic cells, or the appearance of any new lymph node \\>=1.5 centimeters on any axis. Progression for PR/MR is either a \\>=25% increase in IgM from the lowest attained response value or progression of lymphadenopathy, organomegaly, cytopenias, or other clinically significant signs/symptoms caused by WM.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Participants received ofatumumab intravenously (IV) in Cycle 1 (defined as a treatment period of up to 4 weeks \\[Weeks (Wk.) 1 through 4\\]) (300 milligrams \\[mg\\] at Week 1 and 1000 mg at Weeks 2 through 4) and were followed up for 11 weeks (Weeks 5-16). After Week 16, during the Redosing Cycle (RC), participants who had Minor Response or stable disease after Cycle 1 and had not received another Waldenstrom's Macroglobulinemia (WM) therapy received 300 mg IV ofatumumab at Week 1 and 2000 mg IV ofatumumab at Weeks 2 through 5. Participants who achieved a response in either Cycle 1 or the RC and subsequently progressed before 36 months entered Cycle 2 of treatment and received IV ofatumumab 300 mg at Week 1 and IV ofatumumab 2000 mg during Weeks 2 through 5.","id":"OG000","title":"300 mg Ofatumumab, Wk. 1; 1000/2000 mg Ofatumumab, Wk. 2-4/2-5"},{"description":"Participants received ofatumumab IV at 300 mg at Week 1 and 2000 mg at Weeks 2 through 5 in Cycle 1 (defined as a treatment period of up to 5 weeks \\[Weeks 1 through 5\\]) and were followed up for 10 weeks (Weeks 6-16). After Week 16, during the RC, participants who had Minor Response or stable disease after Cycle 1 and had not received another WM therapy received 300 mg IV ofatumumab at Week 1 and 2000 mg IV ofatumumab at Weeks 2 through 5. Participants who achieved a response and subsequently progressed before 36 months entered Cycle 2 of treatment and received 300 mg at Week 1 and 2000 mg during Weeks 2 through 5.","id":"OG001","title":"300 mg Ofatumumab, Wk. 1; 2000 mg Ofatumumab, Wk. 2-5"}],"paramType":"MEDIAN","populationDescription":"ITT Population. Only those participants classified as responders were included in the analysis. Participants who had disease progression or death were counted as events, and other participants were censored at the date of the last adequate assessment in the study.","reportingStatus":"POSTED","timeFrame":"From baseline up to approximately 5 years","title":"Duration of Response for All Responders (CR, PR, MR), as Assessed by the Investigator","type":"SECONDARY","typeUnitsAnalyzed":"events","unitOfMeasure":"days"}